A central point in the profile of Bendamustine is the relationship between its molecular action and the cancer setting in which it is used. Forms DNA cross-links and causes DNA damage with both alkylating and purine-analog-like properties. The cytotoxic effect arises from damaging tumor-cell DNA, a mechanism that supports use across several malignancies and also contributes to treatment-related toxicity. The record identifies it as Alkylating-like nitrogen mustard within Chemotherapy; Alkylating Agent and lists NHL; CLL; SLL among the associated tumor types. The principal indications are Indolent B-cell non-Hodgkin lymphomas; CLL; other selected lymphoid malignancies. Regimen examples include Bendamustine + rituximab (BR); bendamustine-based lymphoma regimens. The combination context matters: depending on the disease, the agent may be used alone or alongside other systemic treatments as specified in the database. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Any biomarker or disease-state requirement included in the indication should be considered when interpreting the entry. The same broad therapeutic class can contain medicines with different targets and therefore different clinical uses. This description intentionally remains descriptive rather than prescriptive, with no patient-specific dosing or treatment instructions. Current labels and applicable oncology guidelines should be consulted to confirm present-day indications and combinations.